摘要
目的在中国医疗环境下评估安络化纤丸联合恩替卡韦治疗慢性乙型肝炎的经济性。方法从医疗保障支付方角度出发,以安络化纤丸联合恩替卡韦治疗慢性乙型肝炎的最新临床研究结果作为数据来源构建Markov模型。试验组均为安络化纤丸联合恩替卡韦,对照组均为单独使用恩替卡韦。运用Treeage pro 2011对2种治疗方案进行成本-效用分析和敏感性分析。结果模型模拟30个周期后,安络化纤丸联合恩替卡韦的总成本和健康产出分别为139265.06元和8.05 QALYs;单独使用恩替卡韦的总成本和健康产出分别为125026.89元和7.11 QALYs;增量成本-效果比(incremental cost effectiveness ratio,ICER)为15146.99元/QALY,约占2022年我国人均GDP(85698元)的1/5,约占2022年全国居民人均可支配收入(36883元)的2/5。敏感性分析显示本研究模型结果较为稳定。结论在治疗慢性乙型肝炎方面,相比单独使用恩替卡韦治疗,安络化纤丸联合恩替卡韦治疗是具有成本-效用优势和药物经济学优势的治疗方案。
Objective To evaluate the economics of Anluo Huaxian Pill(安络化纤丸)combined with entecavir in the treatment of chronic hepatitis B in the Chinese healthcare setting.Methods From the perspective of medical insurance payers,the latest clinical research results of Anluo Huayxian Pill combined with entecavir in the treatment of chronic hepatitis B were used as data sources to build a Markov model.The experimental groups were treated with Anluo Huayxian Pill combined with entecavir,while the control groups were treated with entecavir alone.Cost-effectiveness analysis and sensitivity analysis were performed with Treeage pro 2011 for the two treatments.Results After 30 cycles of model simulation,the total cost and health output of Anluo Huaxian Pill combined with entecavir were 139265.06 yuan and 8.05 QALYs,respectively.The total cost and health outcomes of entecavir alone were 125026.89 yuan and 7.11 QALYs,respectively.Incremental cost effectiveness ratio(ICER)was 15146.99 yuan/QALY,accounting for about 1/5 of the Cinese per capita GDP in 2022(85698 yuan),and about 2/5 of the per capita disposable income of national residents in 2022(36883 yuan).Sensitivity analysis showed that the results of this model are stable.Conclusion In the treatment of chronic hepatitis B,compared with entecavir alone,Anluo Huaxian Pill combined with entecavir is a cost-effectiveness and pharmacoeconomic therapy.
作者
徐龙辰
王葳
卢斯琪
周佳孟
朱文涛
刘森林
刘文林
XU Long-chen;WANG Wei;LU Si-qi;ZHOU Jia-meng;ZHU Wen-tao;LIU Sen-lin;LIU Wen-lin(School of Management,Beijing University of Chinese Medicine,Beijing 100029,China;Handan Chaoyang Hospital,Handan 056103,China)
出处
《中草药》
CAS
CSCD
北大核心
2023年第16期5321-5328,共8页
Chinese Traditional and Herbal Drugs
基金
中央高校基本科研业务费专项(2020-JYB-ZDGG-072)。
